MedTrace Logo

Epidemiology of MDR-TB in Peru

NCT00676754 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 18544

Last updated 2013-03-29

No results posted yet for this study

Summary

The purpose of this study is to better understand tuberculosis (TB) and the risk of infection with TB, in Peru. TB is a disease that is caused by bacteria and transmitted through droplets in the air that come from the lungs of an infected person. The risk of infection will be compared between two groups: household members, who live with people having TB that does not respond well to treatment and household members, who live with people having TB that responds well to treatment. Study participants will include 4,500 TB infected people and 22,500 of their household contacts. Study procedures include answering a questionnaire, TB skin tests, blood samples, and a chest x-ray. Individuals with symptoms indicating TB will be asked to provide sputum samples. Individuals with TB will be involved in the study for up to 48 months; household contacts will be involved in the study for 12 months. The knowledge gained from this study will be used to improve tuberculosis control.

Conditions

  • TB Multi-drug Resistant

Interventions

PROCEDURE

Statens Serum Institut RT23 2TU tuberculin

Sponsors & Collaborators

  • Harvard School of Public Health (HSPH)

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Socios En Salud Sucursal, Peru

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Harvard University Faculty of Medicine

    lead OTHER

Principal Investigators

  • Megan Murray, MD, ScD · Harvard Medical School (HMS and HSDM)

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676754 on ClinicalTrials.gov